Compare CMTL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | IPHA |
|---|---|---|
| Founded | 1967 | 1999 |
| Country | United States | France |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 169.6M |
| IPO Year | 2024 | N/A |
| Metric | CMTL | IPHA |
|---|---|---|
| Price | $5.60 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | ★ 258.5K | 19.8K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | $1.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $1.57 |
| 52 Week High | $6.21 | $2.63 |
| Indicator | CMTL | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | N/A |
| Support Level | $5.34 | N/A |
| Resistance Level | $6.15 | N/A |
| Average True Range (ATR) | 0.37 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 40.00 | 0.00 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.